Semaglutide vs Tirzepatide: Research Comparison

Semaglutide and tirzepatide are the two most extensively studied incretin-class peptides in published clinical literature. Both target the GLP-1 receptor, but tirzepatide adds a second mechanism — GIP receptor agonism — that has produced notable differences in published trial outcomes. This guide compares the two compounds based strictly on published, peer-reviewed data.

Head-to-Head Comparison

Parameter	Semaglutide	Tirzepatide
Full name	Semaglutide	Tirzepatide
Branded versions	Ozempic, Wegovy, Rybelsus	Mounjaro, Zepbound
Developer	Novo Nordisk	Eli Lilly
Mechanism	GLP-1 receptor agonist	Dual GLP-1 + GIP receptor agonist
Molecular weight	4,113.58 Da	4,813.45 Da
Half-life	~165 hours (7 days)	~120 hours (5 days)
Administration	Subcutaneous, once weekly	Subcutaneous, once weekly
First FDA approval	2017 (Ozempic for T2D)	2022 (Mounjaro for T2D)

Mechanism of Action

Semaglutide is a pure GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centres. Its modifications (Aib8, C-18 fatty diacid acylation) extend its half-life from minutes to approximately one week.

Tirzepatide is a dual GLP-1/GIP receptor agonist — the first approved compound in this class. It incorporates a single peptide chain with activity at both receptors. The GIP (glucose-dependent insulinotropic polypeptide) receptor component is hypothesised to contribute additional metabolic effects, including improved lipid handling, enhanced adipose tissue insulin sensitivity, and potentially complementary effects on energy balance (Samms et al., Molecular Metabolism 2022).

The mechanistic question of whether dual agonism produces genuinely additive effects — or whether tirzepatide's results are primarily driven by its GLP-1 activity at high doses — remains an active area of investigation in the research community.

Published Trial Data: Weight Outcomes

Trial	Compound	Dose	Duration	Mean Weight Change	Reference
STEP 1	Semaglutide	2.4 mg/wk	68 weeks	-14.9%	Wilding et al., NEJM 2021
STEP 5	Semaglutide	2.4 mg/wk	104 weeks	-15.2%	Garvey et al., Nat Med 2022
SURMOUNT-1	Tirzepatide	5 mg/wk	72 weeks	-15.0%	Jastreboff et al., NEJM 2022
SURMOUNT-1	Tirzepatide	10 mg/wk	72 weeks	-19.5%	Jastreboff et al., NEJM 2022
SURMOUNT-1	Tirzepatide	15 mg/wk	72 weeks	-22.5%	Jastreboff et al., NEJM 2022

Direct cross-trial comparison has inherent limitations (different populations, enrolment criteria, and trial designs). However, the SURMOUNT-1 data at the 15 mg dose represented the largest mean body weight reduction published for any single pharmaceutical compound when it was reported. The SURPASS-2 trial (Frías et al., NEJM 2021) provided a direct head-to-head comparison in type 2 diabetes, where tirzepatide 15 mg demonstrated statistically superior HbA1c reduction compared to semaglutide 1 mg.

Cardiovascular Outcomes

This is where the two compounds diverge most significantly in the current evidence base:

Semaglutide has completed cardiovascular outcomes data. The SELECT trial (Lincoff et al., NEJM 2023) — 17,604 participants, mean follow-up 39.8 months — demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE). This is landmark data: the first demonstration that an incretin compound reduces cardiovascular events independent of glycaemic control.

Tirzepatide does not yet have published cardiovascular outcomes data. The SURPASS-CVOT trial is ongoing but results have not been published as of this writing. Until that data is available, tirzepatide's cardiovascular profile remains an open question.

Dosing Studied in Published Research

Parameter	Semaglutide	Tirzepatide
Starting dose studied	0.25 mg/week	2.5 mg/week
Target dose studied	2.4 mg/week	5, 10, or 15 mg/week
Escalation period	16 weeks (5 steps)	20 weeks (4-week intervals)
Escalation schedule	0.25 → 0.5 → 1.0 → 1.7 → 2.4	2.5 → 5.0 → 7.5 → 10.0 → 12.5 → 15.0

Side Effect Profiles in Published Literature

Both compounds share a gastrointestinal side effect profile characteristic of GLP-1 receptor agonism. Published rates from their respective pivotal trials:

Adverse Event	Semaglutide 2.4mg (STEP 1)	Tirzepatide 15mg (SURMOUNT-1)
Nausea	44.2%	33.3%
Diarrhoea	31.5%	25.4%
Vomiting	24.8%	12.2%
Constipation	23.4%	11.7%
Discontinuation due to AE	7.0%	6.2%

In published data, gastrointestinal adverse events were generally described as mild-to-moderate in severity, most common during the dose escalation phase, and transient in the majority of participants. Tirzepatide's lower reported GI rates may reflect the different dose escalation schedule, the GIP receptor component, or population differences between trials.

Which Compound for Which Research Question?

The choice between semaglutide and tirzepatide depends on the specific research question:

• Cardiovascular research: Semaglutide has the only published CV outcomes data in this class (SELECT trial). It is the reference compound for cardiovascular-related incretin research
• Metabolic research (weight/glucose): Tirzepatide's SURMOUNT data shows the largest published weight reductions. The dual mechanism offers a distinct pharmacological profile for studying GIP receptor contributions
• Established protocols: Semaglutide has a longer publication history and more extensive dosing data across diverse populations
• Novel mechanism investigation: Tirzepatide's dual agonism opens research questions about GIP's role in human metabolism that cannot be studied with semaglutide

For a broader comparison including retatrutide (triple agonist), see the Ozempic Alternatives in Bali guide.

References cited: Wilding et al., NEJM 2021; Garvey et al., Nature Medicine 2022; Jastreboff et al., NEJM 2022; Frías et al., NEJM 2021; Lincoff et al., NEJM 2023; Samms et al., Molecular Metabolism 2022.